Baxter International shares have declined 32.2% over the past 52 weeks, significantly underperforming the S&P 500 Index's 25.4% return over the same time frame. The stock is up 5.9% year-to-date, lagging the SPX's 9.6% gain, though it has risen 14.9% over the past three months, outpacing the index's 11.7% advance. Baxter's first-quarter 2026 revenue reached $2.7 billion, up about 3% year-over-year and beating analyst estimates, driven by a roughly 12% increase in international sales to $1.3 billion that offset a roughly 4% decline in U.S. sales to $1.4 billion. The company reaffirmed its full-year adjusted EPS guidance of $1.85 to $2.05. Analysts maintain a consensus Hold rating with a mean price target of $20.36, a marginal premium to current levels.
Baxter International IncArticle reports past price decline and Q1 revenue beat with reaffirmed guidance, but no new catalyst; stock performance mixed.
Intuitive Surgical Inc